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W orldwide, cardiovascular disease (CVD) is the largestsingle cause of death among women, accounting for
one third of all deaths (1). In many countries, including the
United States, more women than men die every year of CVD,
a fact largely unknown by physicians (2,3). The public health
impact of CVD in women is not related solely to the mortality
rate, given that advances in science and medicine allow many
women to survive heart disease. For example, in the United
States, 38.2 million women (34%) are living with CVD, and
the population at risk is even larger (2). In China, a country
with a population of approximately 1.3 billion, the age-
standardized prevalence rates of dyslipidemia and hyperten-
sion in women 35 to 74 years of age are 53% and 25%,
respectively, which underscores the enormity of CVD as a
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global health issue and the need for prevention of risk factors
in the first place (4). As life expectancy continues to increase
and economies become more industrialized, the burden of
CVD on women and the global economy will continue to
increase (5).
The human toll and economic impact of CVD are difficult
to overstate. In the United States alone, $403 billion was
estimated to be spent in 2006 on health care or in lost
productivity as a result of CVD, compared with $190 billion
for cancer and $29 billion for human immunodeficiency virus
(HIV) (2). In addition to population-based and macroeco-
nomic interventions, interventions in individual patients are
key to reducing the incidence of CVD globally (6). Preven-
tion of CVD is paramount to the health of every woman and
every nation. Even modest control could have an enormous
impact. It is projected that a reduction in the death rate due to
chronic diseases by just 2% over 1 decade would prevent 36
million deaths (6).
Fortunately, most CVD in women is preventable. In 1999,
the American Heart Association (AHA) published a scientific
statement titled “A Guide to Preventive Cardiology in
Women,” which was based on a 1997 review of the literature
that documented unique aspects of risk factor management
and the occurrence of CVD in women (7,8). Over the
subsequent decade, many landmark clinical trials in the
prevention of CVD altered the practice of medicine. In 2003,
a systematic literature search was conducted to develop
evidence-based guidelines for the prevention of CVD in
women (9). Demand for clinical trial evidence increased in
the wake of the Women’s Health Initiative’s discordant
findings with observational studies of hormone therapy (10).
Some commonly used preventive interventions lacked clini-
cal trial data for women, and it was unclear whether results of
studies conducted in men could be generalized to women.
Since the 2003 literature review, numerous clinical trials that
have a bearing on CVD prevention in women have been
completed (see Appendix). These new research findings must
be interpreted in the context of existing data and as-yet
missing information so they can be translated appropriately
into practice. With few exceptions (eg, the use of aspirin for
primary prevention of heart disease), recommendations to
prevent CVD in women do not differ from those for men.
Healthcare providers should be aware that in some instances,
the risk-reducing interventions recommended in these guide-
lines (eg, angiotensin-converting enzyme inhibitors and an-
giotensin receptor blockers for blood pressure control) are
contraindicated in women contemplating pregnancy or in
those who are pregnant.
This 2007 update provides the most current clinical rec-
ommendations for the prevention of CVD in women 20
years of age and is based on a systematic search of the
highest-quality science, interpreted by experts in the fields of
cardiology, epidemiology, family medicine, gynecology, in-
ternal medicine, neurology, nursing, public health, statistics,
and surgery. These guidelines cover the primary and second-
ary prevention of chronic atherosclerotic vascular diseases.
More acute management of vascular disease in the peripro-
cedural or immediate posthospital settings and of valvular
heart disease is covered in other AHA guidelines. Manage-
ment of heart failure, atrial fibrillation for stroke prevention,
and CVD risk factors during pregnancy is beyond the scope
of the present document.
CVD Risk Assessment in Women
The 2004 guidelines emphasized the importance of recogniz-
ing the spectrum of CVD and thus classified women as being
at high risk, intermediate risk, lower risk, and optimal risk.
Classification was based on clinical criteria and/or the Fra-
mingham global risk score (11). These criteria are still used to
help guide lipid therapy. The 2007 update recommends a
scheme for a general approach to the female patient that
classifies her as at high risk, at risk, or at optimal risk (Table
1). The rationale for the change includes several factors: (1)
The average lifetime risk for CVD in women is very high,
approaching 1 in 2, so prevention is important in all women
(12,13); (2) most clinical trial data used to formulate the
recommendations included either women at high risk because
of known CVD or apparently healthy women with a spectrum
of risk, which allowed the current scheme to align the
guidelines with the evidence; and (3) there has been a
growing appreciation of the limitations of risk stratification
with the Framingham risk function in diverse populations of
women, including the narrow focus on short-term (10-year)
risk of myocardial infarction and coronary heart disease
TABLE 1. Classification of CVD Risk in Women
Risk Status Criteria
High risk Established coronary heart disease
Cerebrovascular disease
Peripheral arterial disease
Abdominal aortic aneurysm
End-stage or chronic renal disease
Diabetes mellitus
10-Year Framingham global risk 20%*
At risk 1 major risk factors for CVD, including:
Cigarette smoking
Poor diet
Physical inactivity
Obesity, especially central adiposity
Family history of premature CVD (CVD at 55 years
of age in male relative and 65 years of age
in female relative)
Hypertension
Dyslipidemia
Evidence of subclinical vascular disease
(eg, coronary calcification)
Metabolic syndrome
Poor exercise capacity on treadmill test and/or
abnormal heart rate recovery after stopping exercise
Optimal risk Framingham global risk 10% and a healthy lifestyle,
with no risk factors
CVD indicates cardiovascular disease.
*Or at high risk on the basis of another population-adapted tool used to
assess global risk.
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death, lack of inclusion of family history, overestimation or
underestimation of risk in nonwhite populations, and the
documentation of subclinical disease among many women
who score as being at low risk (14).
The panel believed that a Framingham global risk score
20% could be used to identify a woman at high risk but that
a lower score is not sufficient to ensure that an individual
woman is at low risk. Even the presence of a single risk factor
at 50 years of age is associated with a substantially increased
lifetime absolute risk for CVD and shorter duration of
survival (13). Women who are at risk of CVD because they
have 1 risk factor for heart disease, evidence of subclinical
disease with or without risk factors, poor exercise capacity, or
unhealthy lifestyles may have a broad range of risk for CVD.
For example, a woman found to have coronary calcification
or increased carotid intimal thickness may be at low absolute
risk of CHD on the basis of the Framingham score, but she
may actually be at intermediate or high risk of a future CVD
event. Healthcare providers should take several factors into
consideration, including medical and lifestyle history, Fra-
mingham risk score, family history of CVD, and other genetic
conditions (eg, familial hypercholesterolemia), as they make
decisions about the aggressiveness of preventive therapy. The
optimal risk category has been maintained in the present
update and emphasizes the importance of optimizing modifi-
able risk, especially with regard to maintaining a healthy
lifestyle, and may reassure some women or motivate others.
The role that novel CVD risk factors (eg, high-sensitivity
C-reactive protein) and novel screening technologies (eg,
coronary calcium scoring) should play in guiding preventive
interventions is not yet defined. Further research is needed on
added benefits, risks, and costs associated with such strate-
gies before they can be incorporated into guidelines. Unique
opportunities to identify women’s risk (eg, during pregnancy)
also deserve further exploration. For example, preeclampsia
may be an early indicator of CVD risk (15,16). Women with
preeclampsia/eclampsia are significantly more likely to de-
velop hypertension and cerebrovascular disease (15,16). In
addition, maternal placental syndromes in combination with
traditional cardiovascular risk factors, such as prepregnancy
hypertension or diabetes mellitus, obesity, dyslipidemia, or
metabolic syndrome, may be additive in defining CVD risk in
women (16). Future research should evaluate the potential for
events or medical contact during unique phases in a woman’s
lifespan, such as adolescence, pregnancy, and menopause, to
identify women at high risk and to determine the effective-
ness of preventive interventions during critical time periods.
Several important changes from the 2004 guidelines should
be noted. First, the approach to risk stratification of women
places greater emphasis on lifetime risk than on short-term
absolute risk, defined by the Framingham global score, in part
because of the limitations described above. The panel ac-
knowledged that nearly all women are at risk for CVD, which
underscores the importance of a heart-healthy lifestyle. Ad-
ditionally, some women are at high risk of future events
because of established CVD and/or multiple risk factors.
These women are candidates for more aggressive preventive
therapy. Second, more definitive data about menopausal
therapy, aspirin therapy, and folic acid therapy have been
published in recent years, and the guidelines have been
revised accordingly. Of note is that aspirin therapy should be
considered for all women for stroke prevention, depending on
the balance of risks and benefits. Finally, an algorithm is
provided to assist healthcare providers in evaluating CVD
risk in women and prioritizing preventive interventions.
Methods
Selection of Expert Panel
The AHA Manuscript Oversight Committee commissioned
the update of the guidelines and approved the chair of the
expert panel, who was a nonvoting member of the panel. The
leadership of each AHA scientific council and interdiscipli-
nary working group was asked to nominate a recognized
expert in CVD prevention who had particular knowledge
about women. Major professional or government organiza-
tions with a mission consistent with CVD prevention were
solicited to serve as cosponsors and were each asked to
nominate 1 representative with full voting rights to serve on
the expert panel. Each panel member completed a conflict-
of-interest statement and was asked to abstain from discus-
sion of or voting on any recommendations they deemed to be
a potential conflict of interest. Panelists also suggested
diverse professional and community organizations to endorse
the final document after its approval by the AHA Science
Advisory and Coordinating Committee and cosponsoring
organizations.
Selection of Topics and Systematic Search
The expert panel reviewed the list of recommendations in the
2004 guidelines and suggested additional topics to be re-
searched to determine whether they warranted discussion or a
clinical recommendation. The methods for the systematic
search were similar to those for the research conducted in
2003 and described previously (9). The time period for the
updated search was January 2003 through June 7, 2006. New
topics were searched electronically on 3 databases from their
inception (Medline, 1966 through June 7, 2006; CINAHL,
1982 through June 7, 2006; and PsychInfo, 1872 through
June 7, 2006).
Briefly, studies were included if they were randomized
clinical trials or large prospective cohort studies (1000
subjects) of CVD risk–reducing interventions, meta-anal-
yses that used a quantitative systematic review process, or
surrogate end-point studies with at least 10 cases of major
clinical CVD end points reported. The systematic search
was conducted by the Duke Center for Clinical Health
Policy Research, Durham, NC. Table 2 lists the number of
articles included/excluded for each category of recommen-
dation. A total of 5774 articles were initially identified;
828 were included for full-text screening, and 246 met the
inclusion criteria and were included in the evidence tables.
Some proposed new topics were searched but not included
in the guidelines because the expert panel determined the
data were insufficient to make clinical recommendations
(eg, yoga/stress reduction) or because the topic had been
covered in other recent guidelines (eg, treatment of atrial
fibrillation for stroke prevention) (17,18). The summary
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evidence used by the expert panel can be obtained online
as a Data Supplement.
Evidence Rating and Recommendation Procedures
A series of conference calls to discuss recommendations was
conducted. Primary and secondary reviewers were assigned
to each recommendation to modify any wording and to ensure
that the evidence tables were complete for that topic. Each
expert received a final copy of the evidence tables and voted
independently on the strength of the recommendation (Class
I, IIa, IIb, or III) and level of evidence (A, B, or C) as outlined
in Table 3. The final rating of evidence was determined by a
majority vote. Modifications to text and clinical recommen-
dations were made on the basis of peer review comments and
cosponsor reviews. The guidelines were then finalized and
approved by the expert panel.
Clinical Recommendations and Limitations
Evidence-based recommendations for the prevention of CVD
in women are listed in Table 4. Each recommendation is
accompanied by the strength of recommendation and the
level of evidence to support it. The strength of the recom-
mendation is based not only on the level of evidence to
support a clinical recommendation but also on other factors,
such as the feasibility of conducting randomized controlled
trials in women. Recommendations are grouped in the fol-
lowing categories: lifestyle interventions, major risk factor
interventions, and preventive drug interventions. Table 5 lists
Class III interventions that are not recommended for the
prevention of CVD, or myocardial infarction in particular, on
the basis of current evidence.
The expert panel tried to simplify the guidelines as much as
possible while attempting to preserve the integrity of the
evidence-based process. This required the assumption of a
TABLE 2. Summary of Articles Identified From Systematic Literature Review, by Topic (2006)
Topic
Abstracts
Identified
Articles Included for
Full-Text Screening
Meta-Analyses
Identified
Articles Included for
Evidence Tables
Hyperlipidemia 166 27 5 9
Physical activity 298* 53† 1 11
Smoking 281 71 0 1
Antiplatelet therapy 402 95‡ 7 12
Hypertension 78 32 1 10
-Blocker therapy 234 17 1 4
Cardiac rehabilitation 298* 53† 3 3
ACE/ARB therapy 251 44 7 13
Weight management 52 4 0 1
Diabetes mellitus 119 14 2 8
Hormone replacement therapy/SERMs§ 154 24 1 10
Diet modification 144 123‡ 1 28
Warfarin, antiplatelet therapy,§ and antiarrhythmic
therapy§ in atrial fibrillation
460 73 23 27
Aspirin for primary prevention 7 95† 2 1
Psychosocial§/depression 409 42 0 10
Antioxidant supplementation 48 13 3 5
Omega-3 fatty acid supplementation 87 23 3 4
Folic acid supplementation, vitamin B6,§ vitamin B12§ 192 36 0 8
New search terms
Alcohol 325 123‡ 0 57
CHF rehabilitation 388 31 4 3
PVD rehabilitation 94 22 0 0
Yoga/stress reduction 83 20 2 6
Aldosterone blocker 239 7 0 4
Stroke rehabilitation 1263 57 11 11
Total 5774 828 77 246
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; SERMs, selective estrogen-receptor modulators;
CHF, congestive heart failure; and PVD, peripheral vascular disease.
*Physical activity and cardiac rehabilitation were combined during the initial literature search and full-text screening phase. This
number reflects the total number of abstracts identified and articles included at full text as physical activity or cardiac rehabilitation.
†Antiplatelet therapy for coronary artery disease and aspirin for primary prevention were combined during the full-text screening
phase. This number reflects the total number of articles included at full text as antiplatelet therapy for coronary artery disease or
aspirin for primary prevention.
‡Diet modification and alcohol were combined during the full-text screening phase. This number reflects the total number of articles
included at full text as diet modification or alcohol.
§New search term for 2006 combined with previous 2003 topic.
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class effect for most therapeutic interventions, and it should
be noted that data are limited with regard to gender differ-
ences in any potential class effects. Although most agents in
a single therapeutic class share similar efficacy in reducing
CVD risk, the safety profiles and costs may vary significantly
among agents; healthcare providers should take these factors
into consideration as they prescribe pharmacotherapy to
prevent CVD.
The panel also emphasizes that the effectiveness of thera-
pies prescribed in the actual office or hospital setting may
vary substantially from the efficacy and safety profiles
observed in clinical trials because of wide variations in
patient characteristics and adherence to therapy as prescribed.
Guideline development has limitations related to the gener-
alizability of results from one population to another. The net
clinical impact of an intervention may not be reflected in the
scope of CVD outcomes evaluated in these guidelines.
Moreover, many studies used to formulate recommendations
did not include older women, especially those 80 years of
age, in whom CVD and comorbidities are common. Health-
care providers should use clinical judgment about the aggres-
siveness of preventive interventions in all women, especially
older women.
Guideline Implementation
A suggested algorithm for the prevention of CVD in women
that incorporates the updated guidelines is presented in the
Figure. Although a comprehensive plan to maximize imple-
mentation of the guidelines in various practice settings is
beyond the scope of this document, barriers to CVD preven-
tion should be discussed with women. A previous study by
the AHA has documented numerous barriers to heart health in
women; chief among them was confusion by mixed messages
from the media (21). Other barriers that healthcare providers
can address were as follows: 36% of women did not perceive
themselves to be at risk, 25% said their healthcare provider
did not say heart health was important, and 1 in 5 said
healthcare providers did not clearly explain how they could
change their risk status (21). Physicians have cited lack of
insurance coverage as a barrier to assisting their patients with
lifestyle changes (3).
Widespread documentation of lack of adherence to CVD
prevention guidelines is available, even among women at
high risk of CVD in managed-care settings in the United
States in which access and medication coverage are available
(22). Policy makers, healthcare providers, and patients all
have roles to play in maximizing adherence to preventive
interventions and reducing the burden of CVD. It is also
important to recognize that although the causes of CVD are
common to all parts of the world, the approaches to its
prevention at the societal or individual level will differ among
countries for cultural, social, medical, and economic reasons
(23).
Research Needs and Future Directions
The expert panel suggested several gaps in knowledge related
to the prevention of CVD that must be addressed to optimize
the cardiovascular health of women. More rigorous testing of
the impact of guidelines themselves on prevention of risk
factors, slowing the progression of risk factors, and reducing
the burden of CVD is needed. The development and testing of
effective methods to implement guidelines in various health-
care settings, at work sites, and in communities are also
research priorities. The role of communication of risk and
barriers to CVD prevention should be studied and incorpo-
rated into creative methods to disseminate and implement
guidelines among diverse populations of women.
The role of genetics in risk stratification and in the
responsiveness to preventive interventions is an active and
important area of research. Likewise, the role of gender and
sex hormones requires further study to understand how they
affect outcomes after interventions and how female sex may
modify the prognostic value of new biomarkers and measures
of subclinical CVD.
Population-wide strategies are necessary to combat the
pandemic of CVD in women, because individually tailored
interventions alone are likely insufficient to maximally pre-
vent and control CVD. Public policy as an intervention to
reduce gender-based disparities in CVD preventive care and
improve cardiovascular outcomes among women must be-
come an integral strategy to reduce the global burden of
CVD.
TABLE 3. Classification and Levels of Evidence
Strength of Recommendation
Classification
Class I Intervention is useful and effective.
Class IIa Weight of evidence/opinion is in favor of
usefulness/efficacy.
Class IIb Usefulness/efficacy is less well established
by evidence/opinion.
Class III Intervention is not useful/effective
and may be harmful.
Level of evidence
A Sufficient evidence from multiple
randomized trials
B Limited evidence from single randomized trial
or other nonrandomized studies
C Based on expert opinion, case studies,
or standard of care
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TABLE 4. Guidelines for Prevention of CVD in Women: Clinical Recommendations
Lifestyle interventions
Cigarette smoking
Women should not smoke and should avoid environmental tobacco smoke. Provide counseling, nicotine replacement, and other pharmacotherapy as indicated
in conjunction with a behavioral program or formal smoking cessation program (Class I, Level B).
Physical activity
Women should accumulate a minimum of 30 minutes of moderate-intensity physical activity (eg, brisk walking) on most, and preferably all, days of the week
(Class I, Level B).
Women who need to lose weight or sustain weight loss should accumulate a minimum of 60 to 90 minutes of moderate-intensity physical activity (eg, brisk
walking) on most, and preferably all, days of the week (Class I, Level C).
Rehabilitation
A comprehensive risk-reduction regimen, such as cardiovascular or stroke rehabilitation or a physician-guided home- or community-based exercise training
program, should be recommended to women with a recent acute coronary syndrome or coronary intervention, new-onset or chronic angina, recent
cerebrovascular event, peripheral arterial disease (Class I, Level A), or current/prior symptoms of heart failure and an LVEF 40% (Class I, Level B).
Dietary intake
Women should consume a diet rich in fruits and vegetables; choose whole-grain, high-fiber foods; consume fish, especially oily fish,* at least twice a week;
limit intake of saturated fat to 10% of energy, and if possible to 7%, cholesterol to 300 mg/d, alcohol intake to no more than 1 drink per day,† and
sodium intake to 2.3 g/d (approximately 1 tsp salt). Consumption of trans-fatty acids should be as low as possible (eg, 1% of energy) (Class I, Level B).
Weight maintenance/reduction
Women should maintain or lose weight through an appropriate balance of physical activity, caloric intake, and formal behavioral programs when indicated to
maintain/achieve a BMI between 18.5 and 24.9 kg/m2 and a waist circumference 35 in (Class I, Level B).
Omega-3 fatty acids
As an adjunct to diet, omega-3 fatty acids in capsule form (approximately 850 to 1000 mg of EPA and DHA) may be considered in women with CHD, and
higher doses (2 to 4 g) may be used for treatment of women with high triglyceride levels (Class IIb, Level B).
Depression
Consider screening women with CHD for depression and refer/treat when indicated (Class IIa, Level B).
Major risk factor interventions
Blood pressure—optimal level and lifestyle
Encourage an optimal blood pressure of 120/80 mm Hg through lifestyle approaches such as weight control, increased physical activity, alcohol moderation,
sodium restriction, and increased consumption of fresh fruits, vegetables, and low-fat dairy products (Class I, Level B).
Blood pressure—pharmacotherapy
Pharmacotherapy is indicated when blood pressure is 140/90 mm Hg or at an even lower blood pressure in the setting of chronic kidney disease or
diabetes (130/80 mm Hg). Thiazide diuretics should be part of the drug regimen for most patients unless contraindicated or if there are compelling
indications for other agents in specific vascular diseases. Initial treatment of high-risk women‡ should be with -blockers and/or ACE inhibitors/ARBs, with
addition of other drugs such as thiazides as needed to achieve goal blood pressure (Class I, Level A).
Lipid and lipoprotein levels—optimal levels and lifestyle
The following levels of lipids and lipoproteins in women should be encouraged through lifestyle approaches: LDL-C 100 mg/dL, HDL-C 50 mg/dL,
triglycerides 150 mg/dL, and non–HDL-C (total cholesterol minus HDL cholesterol) 130 mg/dL (Class I, Level B). If a woman is at high risk‡ or has
hypercholesterolemia, intake of saturated fat should be 7% and cholesterol intake 200 mg/d) (Class I, Level B).
Lipids—pharmacotherapy for LDL lowering, high-risk women
Utilize LDL-C–lowering drug therapy simultaneously with lifestyle therapy in women with CHD to achieve an LDL-C 100 mg/dL (Class I, Level A) and
similarly in women with other atherosclerotic CVD or diabetes mellitus or 10-year absolute risk 20% (Class I, Level B).
A reduction to 70 mg/dL is reasonable in very-high-risk women§ with CHD and may require an LDL-lowering drug combination (Class IIa, Level B).
Lipids—pharmacotherapy for LDL lowering, other at-risk women
Utilize LDL-C–lowering therapy if LDL-C level is 130 mg/dL with lifestyle therapy and there are multiple risk factors and 10-year absolute risk 10% to 20%
(Class I, Level B).
Utilize LDL-C–lowering therapy if LDL-C level is 160 mg/dL with lifestyle therapy and multiple risk factors even if 10-year absolute risk is 10% (Class I,
Level B).
Utilize LDL-C–lowering therapy if LDL 190 mg/dL regardless of the presence or absence of other risk factors or CVD on lifestyle therapy (Class I, Level B).
Lipids—pharmacotherapy for low HDL or elevated non–HDL, high-risk women
Utilize niacin or fibrate therapy when HDL-C is low or non–HDL-C is elevated in high-risk women after LDL-C goal is reached (Class IIa, Level B).
Lipids—pharmacotherapy for low HDL or elevated non-HDL, other at-risk women
Consider niacin or fibrate therapy when HDL-C is low or non–HDL-C is elevated after LDL-C goal is reached in women with multiple risk factors and a
10-year absolute risk 10% to 20% (Class IIb, Level B).
Diabetes mellitus
Lifestyle and pharmacotherapy should be used as indicated in women with diabetes (Class I, Level B) to achieve an HbA1C 7% if this can be accomplished
without significant hypoglycemia (Class I, Level C).
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TABLE 5. Class III Interventions (Not Useful/Effective and May Be Harmful) for CVD or MI Prevention in Women
Menopausal therapy
Hormone therapy and selective estrogen-receptor modulators (SERMs) should not be used for the primary or secondary prevention of CVD (Class III, Level A).
Antioxidant supplements
Antioxidant vitamin supplements (eg, vitamin E, C, and beta carotene) should not be used for the primary or secondary prevention of CVD (Class III, Level A).
Folic acid*
Folic acid, with or without B6 and B12 supplementation, should not be used for the primary or secondary prevention of CVD (Class III, Level A).
Aspirin for MI in women <65 years of age†
Routine use of aspirin in healthy women 65 years of age is not recommended to prevent MI (Class III, Level B).
CVD indicates cardiovascular disease; MI, myocardial infarction.
*Folic acid supplementation should be used in the childbearing years to prevent neural tube defects.
†For recommendation for aspirin to prevent CVD in women 65 years of age or stroke in women 65 years of age, please see Table 4.
TABLE 4. Continued
Preventive drug interventions
Aspirin, high risk
Aspirin therapy (75 to 325 mg/d)¶ should be used in high-risk‡ women unless contraindicated (Class I, Level A).
If a high-risk‡ woman is intolerant of aspirin therapy, clopidogrel should be substituted (Class I, Level B).
Aspirin—other at-risk or healthy women
In women 65 years of age, consider aspirin therapy (81 mg daily or 100 mg every other day) if blood pressure is controlled and benefit for ischemic stroke
and MI prevention is likely to outweigh risk of gastrointestinal bleeding and hemorrhagic stroke (Class IIa, Level B) and in women 65 years of age when
benefit for ischemic stroke prevention is likely to outweigh adverse effects of therapy (Class IIb, Level B).
-Blockers
-Blockers should be used indefinitely in all women after MI, acute coronary syndrome, or left ventricular dysfunction with or without heart failure symptoms,
unless contraindicated (Class I, Level A).
ACE inhibitors/ARBs
ACE inhibitors should be used (unless contraindicated) in women after MI and in those with clinical evidence of heart failure or an LVEF 40% or with
diabetes mellitus (Class I, Level A). In women after MI and in those with clinical evidence of heart failure or an LVEF 40% or with diabetes mellitus who are
intolerant of ACE inhibitors, ARBs should be used instead (Class I, Level B).
Aldosterone blockade
Use aldosterone blockade after MI in women who do not have significant renal dysfunction or hyperkalemia who are already receiving therapeutic doses of an
ACE inhibitor and -blocker, and have LVEF 40% with symptomatic heart failure (Class I, Level B).
LVEF indicates left ventricular ejection fraction; BMI, body mass index; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; CHD, coronary heart disease; ACE,
angiotensin-converting enzyme; ARB, angiotensin receptor blocker; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; CVD,
cardiovascular disease; and MI, myocardial infarction.
*Pregnant and lactating women should avoid eating fish potentially high in methylmercury (eg, shark, swordfish, king mackerel, or tile fish) and should eat up to
12 oz/wk of a variety of fish and shellfish low in mercury and check the Environmental Protection Agency and the US Food and Drug Administration’s Web sites for
updates and local advisories about safety of local catch.
†A drink equivalent is equal to a 12-oz bottle of beer, a 5-oz glass of wine, or a 1.5-oz shot of 80-proof spirit.
‡Criteria for high risk include established CHD, cerebrovascular disease, peripheral arterial disease, abdominal aortic aneurysm, end-stage or chronic renal disease,
diabetes mellitus, and 10-year Framingham risk 20%.
§Criteria for very high risk include established CVD plus any of the following: multiple major risk factors, severe and poorly controlled risk factors, diabetes
mellitus (19).
Dietary supplement niacin should not be used as a substitute for prescription niacin.
¶After percutaneous intervention with stent placement or coronary artery bypass grafting within previous year and in women with noncoronary forms of CVD, use
current guidelines for aspirin and clopidogrel (20).
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